Cystectomy vs intravesical BCG therapy: how are they different?

Cystectomy is an operation that removes the bladder and requires a new route for urine to leave the body. Intravesical BCG is placed through a catheter into the bladder, where it stimulates a local immune response. They are not interchangeable steps: one removes the organ, while the other treats the bladder lining in place.

Cystectomy removes the bladder, while intravesical BCG delivers immune treatment into the bladder; the choice depends on tumour features, response, and overall health.

A urology team may discuss cystectomy when the cancer is invasive, has features that make bladder-preserving treatment unsuitable, or remains despite bladder-directed treatment. It may also be considered when repeated examinations show disease that cannot be controlled safely within the bladder. The operation is a major decision because urinary reconstruction and recovery become part of daily care.

BCG may be considered for selected cancers that are confined to the bladder lining and are suitable for local immune treatment. A catheter is used to place the medicine in the bladder, and the care team explains how long it should be held and how follow-up cystoscopies will assess the response. Further courses or a different plan may be discussed if disease returns or does not respond.

After cystectomy, possible concerns include bleeding, infection, blood clots, changes in bowel function, and problems related to the urinary diversion. Recovery can affect movement, eating, wound care, and body image for a time. BCG can cause burning during urination, frequency, urgency, fatigue, or flu-like symptoms. Severe fever, inability to urinate, or feeling acutely unwell needs prompt medical advice because infection or a stronger reaction may require assessment.

The care team may recommend another approach when the tumour needs a different combination of surgery, chemotherapy, radiotherapy, or supportive care. A biopsy, imaging, examination under anaesthesia, and review of earlier treatment can clarify the cancer’s depth and behaviour. If treatment is being delayed because of infection, kidney problems, or another health issue, that problem may be addressed first.

The recommendation usually brings together the tumour stage and grade, number and position of tumours, prior BCG response, bladder function, kidney function, other illnesses, and your priorities. Ask which finding drives the recommendation, what alternatives remain, how urinary function may change, and what follow-up would involve. A second opinion from a urologic oncology team can help when the choices feel finely balanced.